Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates. The current treatment landscape is dominated by IL-17 inhibitors and TNF-α inhibitors, due to their widespread use and inclusion in the National Reimbursement Drug List (NRDL). However, access to advanced therapies remains uneven, especially in rural regions where traditional treatments are still commonly used in place of biologics. Despite recent advances, unmet needs persist—achieving long-term skin clearance, improving quality of life, and effectively managing disease recurrence and progression. The psoriasis market in China is expected to grow steadily over the next decade, driven by the uptake of non-TNF-α biologics and the launch of emerging oral systemic therapies. These agents are expected to expand treatment options and intensify competition in the biologics segment. This report provides stakeholders with a comprehensive analysis of how evolving treatment practices, pricing dynamics, and policy mechanisms—such as inclusion in the NRDL and the impact of Volume-Based Procurement (VBP)—will shape access, uptake, and commercial success in China’s psoriasis market.
Questions Answered
- How is psoriasis currently managed in China, and what are the prevailing treatment patterns?
- What are the key unmet needs in the treatment of psoriasis across different severity levels?
- How will the psoriasis market evolve over the next decade in terms of patient share and sales?
- What are the perspectives of Chinese dermatologists on current and emerging therapies?
- How will NRDL and VBP policies influence access and uptake of branded therapies?
Geography: China
Primary research: Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 dermatologists in China
Epidemiology: Diagnosed prevalence of psoriasis in urban versus rural China, clinically relevant and market-relevant drug-treated populations
Forecast: 10-year, annualized, drug-level sales and patient share of key ulcerative colitis therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions
Drug treatments: Coverage of key current and late-phase emerging therapies
Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)
Product description: China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy in China.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
- Gauge the commercial outlook and impact of key market events.
